HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinical efficacy of new antiepileptic drugs in refractory partial epilepsy: experience in the United States with three novel drugs.

Abstract
A number of new antiepileptic drugs (AEDs), including topiramate (TPM), felbamate (FBM), and gabapentin (GBP), are approved or believed to be close to approval for marketing in the United States. Key efficacy findings for these AEDs in refractory partial epilepsy were reviewed. Large and significant drug-placebo differences were observed with TPM in two large dose-finding trials conducted in the United States. The minimal effective dose of TPM in the population studied was determined to be approximately 200 mg/day, and doses above 600 mg/day produced good efficacy but little incremental benefit versus the lower dosages for the overall study population. FBM is active in partial epilepsy, although seizure reduction is less marked and drug interactions complicate the findings. GBP is also active in this population, but only the 1,800 mg/day dosage was significantly better than placebo with respect to percent responders. It may be useful to explore higher dosage ranges for both FBM and GBP if they can be well tolerated.
AuthorsJ A French
JournalEpilepsia (Epilepsia) Vol. 37 Suppl 2 Pg. S23-S26 ( 1996) ISSN: 0013-9580 [Print] United States
PMID8641243 (Publication Type: Journal Article, Meta-Analysis)
Chemical References
  • Acetates
  • Amines
  • Anticonvulsants
  • Cyclohexanecarboxylic Acids
  • Phenylcarbamates
  • Placebos
  • Propylene Glycols
  • Topiramate
  • Fructose
  • gamma-Aminobutyric Acid
  • Gabapentin
  • Felbamate
Topics
  • Acetates (therapeutic use)
  • Adolescent
  • Adult
  • Aged
  • Amines
  • Anticonvulsants (administration & dosage, adverse effects, therapeutic use)
  • Controlled Clinical Trials as Topic
  • Cyclohexanecarboxylic Acids
  • Drug Administration Schedule
  • Epilepsies, Partial (drug therapy)
  • Felbamate
  • Fructose (analogs & derivatives, therapeutic use)
  • Gabapentin
  • Humans
  • Middle Aged
  • Phenylcarbamates
  • Placebos
  • Propylene Glycols (therapeutic use)
  • Randomized Controlled Trials as Topic
  • Topiramate
  • Treatment Outcome
  • United States
  • gamma-Aminobutyric Acid

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: